Fortress Biotech, Inc. (FBIO) AI Stock Analysis

Fortress Biotech develops and commercializes biopharmaceutical products, operating with a commercialized dermatology portfolio and a pipeline of clinical candidates. Its marketed dermatology treatments include Ximino and Targadox for acne vulgaris, Exelderm for fungal infections, Qbrexza for hyperhidrosis, Luxamend for wound management, and Accutane for severe acne. Its late-stage clinical programs feature intravenous Tramadol for post-operative pain, CUTX-101 for Menkes disease, and MB-107 and MB-207 for severe combined immunodeficiency. The company also advances early-stage therapies including Cosibelimab for metastatic cancers, CK-101 for EGFR mutation-positive NSCLC, CAEL-101 for amyloidosis, and CEVA101 for traumatic brain injury, alongside preclinical gene therapy initiatives.

Fortress Biotech grew revenue from $68.8M in FY2021 to $84.5M in FY2023, before a 31.8% drop brought FY2024 revenue to $57.7M. In FY2025, revenue rebounded 9.7% to $63.3M, and net income reached $6.8M with a net margin of 10.8%, even as operating margin stood at -111.0%. Across five years from FY2020 to FY2025, revenue posted a compound annual growth rate of 6.8%. R&D expenses declined substantially from $128.9M in FY2021 to $11.9M in FY2025. In the trailing twelve months through June 30, 2026, revenue stood at $68.5M, supported by 14.0% year-over-year quarterly revenue growth.

As of June 30, 2026, Fortress Biotech held $196.6M in cash and short-term investments against $64.8M in total debt, resulting in net cash of $131.8M. Total assets were $316.7M, and shareholders' equity was $164.1M, yielding a debt-to-equity ratio of 0.39 and a current ratio of 3.96. In FY2025, free cash flow was -$65.8M and operating cash flow was -$65.8M. Capital returns that year included $265,000 in share buybacks and $664,000 in dividends paid, while share count expanded 563.8% over five years.

At $1.87 per share, Fortress Biotech has a market cap of $62.4M and an enterprise value of -$65.2M. The stock trades at a trailing price-to-earnings multiple of 0.7x and a price-to-sales multiple of 0.9x, compared to medians of 24.6x and 4.1x for its US-listed Healthcare peers. Its forward P/E is 1.2x versus the peer median of 17.3x, and price-to-book is 0.5x. Over the past year, the stock fell 31.8%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 96.0% against an 83.0% gain for the benchmark.

Consensus coverage from 1 analyst reflects a Strong Buy rating with zero Buy, Hold, or Sell ratings. The mean price target is $5.00, representing 167.4% upside compared to the last close of $1.87. For the fiscal year ending December 31, 2026, analysts estimate revenue of $78.8M and EPS of $2.55. For the following fiscal year, 1 analyst projects revenue of $113.2M and EPS of -$1.00. The company beat EPS estimates in 3 of the last 4 quarters, and the next earnings date is November 13, 2026.

This page is an AI-written research summary of Fortress Biotech, Inc. (FBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: FBIO income statement, FBIO balance sheet, FBIO key metrics, FBIO analyst forecast, FBIO chart. See the FBIO stock overview for the latest quote and news.